Skip to main content

Table 4 Categorisation 2: non-high FeNO and non-high blood eosinophils vs. high FeNO and non-high blood eosinophils

From: Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations

Characteristics Non-high FeNO and non-high blood eosinophils (n = 98) High FeNO and non-high blood eosinophils (n = 98) p-value
Sex
 n (% non-missing) 98 (100.0) 98 (100.0) 1.0000
 Male 41 (41.8) 41 (41.8)  
Age
 n (% non-missing) 98 (100.0) 98 (100.0) 1.0000
 Mean (SD) 48.8 (15.3) 48.6 (15.6)  
 Median (IQR) 53.0 (27.0) 53.0 (27.0)  
Age group
 n (% non-missing) 98 (100.0) 98 (100.0) 0.3072
 Under 35 23 (23.5) 24 (24.5)  
 35–65 65 (66.3) 57 (58.2)  
 66–80 10 (10.2) 17 (17.3)  
Smoking status
 n (% non-missing) 98 (100.0) 98 (100.0) 1.0000
 Non-smoker 53 (54.1) 53 (54.1)  
 Ex-smoker 8 (8.2) 8 (8.2)  
 Current smoker 23 (23.5) 23 (23.5)  
BMI
 n (% non-missing) 96 (98.0) 94 (95.9) 0.0063
 Mean (SD) 29.3 (6.2) 26.9 (5.8)  
 Median (IQR) 27.9 (8.6) 25.7 (7.6)  
FeNO
 n (% non-missing) 98 (100.0) 98 (100.0) < 0.0001
 Mean (SD) 17.7 (7.9) 60.0 (31.8)  
 Median (IQR) 17.0 (10.0) 50.0 (25.0)  
Blood eosinophil count
 n (% non-missing) 98 (100.0) 97 (99.0) < 0.0001
 Mean (SD) 0.2 (0.1) 0.3 (0.3)  
 Median (IQR) 0.2 (0.1) 0.3 (0.3)  
Active eczema diagnosisa
 n (% non-missing) 98 (100.0) 98 (100.0) 1.0000
 Yes 4 (4.1) 4 (4.1)  
Active rhinitis diagnosisa
 n (% non-missing) 98 (100.0) 98 (100.0) 0.7492
 Yes 26 (26.5) 28 (28.6)  
Eczema diagnosis
 n (% non-missing) 98 (100.0) 98 (100.0) 0.8763
 Yes 29 (29.6) 30 (30.6)  
Rhinitis diagnosis
 n (% non-missing) 98 (100.0) 98 (100.0) 0.4546
 Yes 32 (32.7) 37 (37.8)  
IHD diagnosis
 n (% non-missing) 98 (100.0) 98 (100.0) 0.7003
 Yes 4 (4.1) 3 (3.1)  
Heart failure diagnosis
 n (% non-missing) 98 (100.0) 98 (100.0)  
 Yes 0 (0.0) 0 (0.0)  
Hypertension diagnosis
 n (% non-missing) 98 (100.0) 98 (100.0) 0.0967
 Yes 29 (29.6) 19 (19.4)  
Diabetes diagnosis
 n (% non-missing) 98 (100.0) 98 (100.0) 0.5513
 Yes 7 (7.1) 5 (5.1)  
GERD active diagnosis
 n (% non-missing) 98 (100.0) 98 (100.0) 0.6018
 Yes 9 (9.2) 7 (7.1)  
Predicted peak flow
 n (% non-missing) 55 (56.1) 71 (72.4) 0.6615
 Mean (SD) 520.7 (67.4) 515.9 (68.6)  
 Median (IQR) 490.8 (137.4) 493.7 (125.0)  
ICS/LABA prescriptions per patient
 n (% non-missing) 98 (100.0) 98 (100.0) 0.1318
 Mean (SD) 2.6 (3.1) 3.4 (3.7)  
 Median (IQR) 1.0 (4.0) 2.0 (5.0)  
Mono ICS prescriptions per patient
 n (% non-missing) 98 (100.0) 98 (100.0) 0.0295
 Mean (SD) 1.6 (2.8) 0.9 (1.9)  
 Median (IQR) 0.0 (2.0) 0.0 (1.0)  
Mean daily SABA dosage (µg)
 n (% non-missing) 98 (100.0) 98 (100.0) 0.3731
 < 100 31 (31.6) 40 (40.8)  
 100–200 32 (32.7) 22 (22.4)  
 201–400 20 (20.4) 22 (22.4)  
 > 400 15 (15.3) 14 (14.3)  
ICS adherenceb
 n (% non-missing) 98 (100.0) 98 (100.0) 0.4778
 Mean (SD) 58.1 (43.5) 65.7 (67.6)  
 Median (IQR) 49.3 (57.5) 49.3 (54.8)  
  1. All values in the table are n (%) unless otherwise specified. High FeNO defined as ≥ 35 ppb; non-high FeNO < 35 ppb; high blood eosinophil count defined as ≥ 0.300 × 109 cells/L; non-high blood eosinophil count < 0.300 × 109 cells/L
  2. BMI body mass index, FeNO fractional exhaled nitric oxide, GERD gastroesophageal reflux disease, ICS inhaled corticosteroid, IHD ischaemic heart disease, IQR interquartile range, LABA long-acting β2-agonist, ppb parts per billion, SABA short-acting β2-agonist, SD standard deviation
  3. aActive denotes diagnosed in the year before FeNO reading or treated in the year before FeNO reading
  4. bMedication Possession Ratio was calculated by dividing the total of 1 day’s supply by the total number of days evaluated, multiplied by 100%. The evaluation period for all patients was 365 days in the study year